GlassScriptPhysician profile
David L Patterson
NPI 1922001007
$251,797.45
in general payments reported to CMS, 2019-2025
42 companies · $2,091 in 2025
The $2,091 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $29K · 2021: $78K · 2022: $45K · 2023: $5,929 · 2024: $7,142 · 2025: $2,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,158 · Food and Beverage: $4,176 · Honoraria: $2,500 · Travel and Lodging: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,158.36 |
| Food and Beverage | $4,175.54 |
| Honoraria | $2,500.00 |
| Travel and Lodging | $1,328.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $142,623.64 | 2019-2024 | Dupixent |
| Genzyme Corporation | $89,225.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $4,602.15 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Adma Biomanufacturing LLC | $3,262.37 | 2024-2025 | |
| Pharming Healthcare, INC. | $3,065.22 | 2022-2025 | Joenja, Ruconest |
| Grifols USA, LLC | $1,958.88 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Consortium of Independent Immunology Clinics, LLC | $1,515.97 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,207.77 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Octapharma USA, INC. | $1,142.82 | 2019-2025 | Cutaquig, Octagam Immune Globulin (Human) |
| Novartis Pharmaceuticals Corporation | $272.86 | 2021-2025 | |
| Pfizer INC. | $272.48 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $271.95 | 2021-2025 | Cuvitru, Hyqvia, Eohilia |
| Covis Pharma Gmbh | $270.38 | 2020-2023 | |
| Kaleo, INC. | $230.67 | 2019-2022 | |
| Optinose US, INC. | $210.13 | 2019-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $200.74 | 2019-2025 | Hizentra |
| Shire North American Group INC | $200.00 | 2019 | |
| Amgen INC. | $142.09 | 2022-2025 | Tezspire, Actimmune, Uplizna |
| Genentech USA, INC. | $141.11 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.14 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $113.33 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $110.56 | 2020-2022 | |
| Blueprint Medicines Corporation | $87.92 | 2023-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $71.36 | 2025 | Neffy |
| Azurity Pharmaceuticals, INC. | $61.99 | 2025 | Alvesco |
| Alk-Abello, INC | $51.96 | 2019-2025 | Timothy, Standardized, Alternaria Tenuis, Standardized Mite D. Farinae |
| Abbvie INC. | $44.54 | 2022 | |
| Merck Sharp & Dohme LLC | $40.88 | 2020-2023 | |
| Bio Products Laboratory USA, INC. | $28.66 | 2021-2022 | |
| Henry Schein, INC. | $21.38 | 2025 | |
| X4 Pharmaceuticals, INC. | $20.95 | 2024 | Xolremdi |
| Uswm, LLC | $20.77 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $19.43 | 2020 | |
| Biomerieux INC | $18.91 | 2023 | |
| Leo Pharma INC. | $18.75 | 2022 | |
| Tersera Therapeutics LLC | $18.26 | 2022 | |
| Dermavant Sciences, INC. | $17.72 | 2024 | Vtama |
| Horizon Therapeutics Plc | $17.47 | 2019 | |
| Invivyd INC | $16.93 | 2025 | Pemgarda |
| Organon LLC | $14.77 | 2025 | Vtama |
| Phadia US INC. | $14.36 | 2024 | Immunocap |
| Hikma Pharmaceuticals USA | $14.01 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,043.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.